Capital Advisory Group Advisory Services’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,056
| Closed | -$1.16M | – | 8 |
|
|
2025
Q4 | $1.16M | Sell |
5,056
-167
| -3% | -$38K | 0.34% | 70 |
|
|
2025
Q3 | $1.21M | Sell |
5,223
-3,176
| -38% | -$647K | 0.38% | 75 |
|
|
2025
Q2 | $1.56M | Sell |
8,399
-52
| -0.6% | -$9.66K | 0.56% | 55 |
|
|
2025
Q1 | $1.77M | Buy |
8,451
+89
| +1% | +$17.3K | 0.68% | 50 |
|
|
2024
Q4 | $1.49M | Buy |
8,362
+461
| +6% | +$84.8K | 0.53% | 57 |
|
|
2024
Q3 | $1.56M | Buy |
7,901
+114
| +1% | +$21.3K | 0.62% | 50 |
|
|
2024
Q2 | $1.34M | Buy |
7,787
+438
| +6% | +$72.6K | 0.57% | 53 |
|
|
2024
Q1 | $1.34M | Buy |
7,349
+41
| +0.6% | +$7.07K | 0.63% | 49 |
|
|
2023
Q4 | $1.13M | Sell |
7,308
-94
| -1% | -$13.7K | 0.61% | 48 |
|
|
2023
Q3 | $1.1M | Buy |
+7,402
| New | +$1.09M | 0.63% | 50 |
|
|
2023
Q2 | – | Sell |
-7,823
| Closed | -$1.25M | – | 80 |
|
|
2023
Q1 | $1.25M | Buy |
7,823
+120
| +2% | +$18.3K | 0.75% | 41 |
|
|
2022
Q4 | $1.24M | Sell |
7,703
-162
| -2% | -$24.8K | 0.85% | 38 |
|
|
2022
Q3 | $1.06M | Sell |
7,865
-42
| -0.5% | -$6.03K | 0.73% | 43 |
|
|
2022
Q2 | $1.2M | Sell |
7,907
-45
| -0.6% | -$6.88K | 0.72% | 42 |
|
|
2022
Q1 | $1.29M | Buy |
7,952
+250
| +3% | +$36.3K | 0.6% | 47 |
|
|
2021
Q4 | $1.04M | Sell |
7,702
-204
| -3% | -$24.1K | 0.45% | 64 |
|
|
2021
Q3 | $853K | Buy |
7,906
+653
| +9% | +$74.6K | 0.31% | 81 |
|
|
2021
Q2 | $817K | Buy |
7,253
+244
| +3% | +$27.5K | 0.3% | 83 |
|
|
2021
Q1 | $759K | Buy |
7,009
+170
| +2% | +$18.2K | 0.3% | 83 |
|
|
2020
Q4 | $733K | Buy |
6,839
+2,219
| +48% | +$213K | 0.31% | 77 |
|
|
2020
Q3 | $405K | Sell |
4,620
-1,096
| -19% | -$103K | 0.21% | 90 |
|
|
2020
Q2 | $561K | Buy |
5,716
+5,536
| +3,076% | +$487K | 0.31% | 73 |
|
|
2020
Q1 | $14K | Buy |
+180
| New | +$15.3K | 0.02% | 198 |
|
|
2019
Q4 | – | Sell |
-176
| Closed | -$14K | – | 197 |
|
|
2019
Q3 | $14K | Sell |
176
-312
| -64% | -$21.4K | 0.01% | 245 |
|
|
2019
Q2 | $35K | Sell |
488
-30
| -6% | -$2.36K | 0.02% | 176 |
|
|
2019
Q1 | $42K | Sell |
518
-9,273
| -95% | -$759K | 0.03% | 156 |
|
|
2018
Q4 | $907K | Sell |
9,791
-647
| -6% | -$56.9K | 0.7% | 27 |
|
|
2018
Q3 | $987K | Sell |
10,438
-42
| -0.4% | -$3.98K | 0.66% | 28 |
|
|
2018
Q2 | $975K | Buy |
10,480
+5,501
| +110% | +$537K | 0.71% | 25 |
|
|
2018
Q1 | $470K | Buy |
+4,979
| New | +$547K | 0.34% | 47 |
|
Other funds holding ABBV
VCM
VPM
Capital Advisory Group Advisory Services's ABBV Position: Q1 2026 in Review
Capital Advisory Group Advisory Services sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 5,056 shares — an estimated $1.16M sold.
Capital Advisory Group Advisory Services first reported a position in ABBV in Q1 2018 and held it in 30 quarters. The position peaked at $1.77M in Q1 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Capital Advisory Group Advisory Services reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
- Capital Advisory Group Advisory Services sold 5,056 AbbVie shares in Q1 2026, an estimated $1.16M.
- Capital Advisory Group Advisory Services first reported a position in AbbVie in Q1 2018 and held it in 30 quarters.
- Capital Advisory Group Advisory Services's AbbVie position peaked at $1.77M in Q1 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Capital Advisory Group Advisory Services's 13F filing for Q1 2026, filed 15 Apr 2026.